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Available online 30 May 2016Chronic heart failure (HF) is a leading clinical and public problem posing a higher risk ofmorbidity andmortality
in different populations. HF appears to be in both phenotypic forms: HF with reduced left ventricular ejection
fraction (HFrEF) and HF with preserved left ventricular ejection fraction (HFpEF). Although both HF phenotypes
can be distinguished through clinical features, co-morbidity status, prediction score, and treatment, the clinical
outcomes in patients with HFrEF and HFpEF are similar. In this context, investigation of various molecular and
cellular mechanisms leading to the development and progression of both HF phenotypes is very important.
There is emerging evidence that epigenetic regulation may have a clue in the pathogenesis of HF. This review
represents current available evidence regarding the implication of epigenetic modiﬁcations in the development
of different HF phenotypes and perspectives of epigenetic-based therapies of HF.
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Chronic heart failure (HF) has remained a serious clinical and public
problem [1]; despite that the prevalence of chronic HF especially HF
with reduced left ventricular ejection fraction (HFrEF) seems to have a
tendency to decrease within the last decade in developed countries
[2]. In contrast, the frequency of new cases of HF with preserved left
ventricular ejection fraction (HFpEF) is on the rise and HFpEF is consid-
ered more common than HFrEF predominantly in the older population
and among subjects with hypertension, diabetes, and respiratorygrant from any funding agency
. This is an open access article underdiseases [3]. Currently, more than 50% of patients with the clinical syn-
drome ofHFmight have a preserved left ventricular ejection fraction [4].
Nevertheless, recent clinical studies have shown a sufﬁcient distinction
between the presentation of both HF phenotypes (HFrEF or HFpEF) in
individuals at risk for HF development in a primary care setting [5,6].
Although HFpEF patients might have lower levels of predictive bio-
markers [7], the clinical outcomes in HFpEF individuals, i.e. cardiovascu-
lar (CV) death, HF-related death, sudden death and readmission, are not
better than in patients with HFrEF [8,9]. Current clinical HF guidelines
recommend the use of early identiﬁcation and treatment of the under-
lying cause of cardiac dysfunction to prevent HF manifestation [10,11],
whereas no evidence exists that HF phenotypes' development is pre-
ventable with speciﬁc medical care [12]. Taken together, all these data
clarify the importance of stratiﬁcation of individuals at risk of HFrEF or
HFpEF development and progression [13,14].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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velopment and progression of both HF phenotypes. There is emerging
evidence showing that the epigenetic regulationmay take an important
part in the pathogenesis of HF playing a pivotal role in the phenotypic
response of a failing heart [15]. Epigenetic modiﬁcations affecting DNA
methylation, ATP-dependent chromatin remodeling, histone modiﬁca-
tions, and microRNA-related mechanisms are considered sufﬁcient
factors contributing to adverse cardiac remodeling and preceding cardi-
ac dysfunction [16]. Probably, in the future epigenetic modiﬁcations of
cardiomyocytes would be a target for personalized management and
much more effective tools for the prevention of HF development [17].
The review summarizes the knowledge regarding the implication
of epigenetic modiﬁcations in the development of different HF
phenotypes.
1.1. Deﬁnition of epigenetics
A classical deﬁnition of epigenetics was proposed by Conrad
Waddington in the 1950s, who believed that an organism's phenotype
arises from its genotype through the so called “programmed epigenetic”
event. Epigenetics was considered neither as the study of changes in
states of any gene activity nor of inherited activity states only [18]. In
some deﬁnitions, only those activity states that are inherited across
cell division were deﬁned [19]. In the Roadmap Epigenomics Project
epigenetics is used as an emerging frontier of science that involves the
study of changes in the regulation of gene activity and expression that
are not dependent on gene sequence [20]. According to the Banbury
Conference Center and Cold Spring Harbor Laboratory, a chromatin-
based epigenetic trait is deﬁned as a stably heritable phenotype
resulting from changes in a chromosome without alterations in the
DNA sequence [21]. By now, it has been suggested that the basis of
epigenetics is non-genetic cellular memory that is expressed or non-
expressed in speciﬁc developmental and environmental situations [22].
Berger et al. in 2009 [21] have suggested using at least three catego-
ries of signals that modulate epigenetic state: “Epigenator”, “Epigenetic
Initiator” and “Epigenetic Maintainer”. The authors proposed a signal
named the “Epigenator” that might be an attribute of the environment
and could be a trigger in an intracellular pathway. The other signal is
called the “Epigenetic Initiator”, and corresponds to the “Epigenator”
signal and is essential for deﬁning the precise arrangement of the epige-
netic chromatin environment. Finally, the “Epigenetic Maintainer” sig-
nal is deemed as the chromatin environment contributing to the ﬁrst
and subsequent generations. The role of different classes of potential
signals affecting epigenetic modiﬁcations of chromatin is not well de-
ﬁned and is widely discussed.
In this context, discrete chemicalmodiﬁcations of DNAand primarily
histones might regulate expression or repression of target genes and
can be transmitted to the descent via epigenetic memory [23]. It has
been suggested that the macro-molecular complex, called the “Epige-
netic Code REplication Machinery” (ECREM), is involved in the inheri-
tance of the epigenetic code. The main the members of ECREM could
be enzymes involved in epigenetic modiﬁcation of chromatin, i.e. DNA
methyltransferases, histone deacetylases, histone acetyltransferases,
and sirtuins. Moreover, deregulated ECREM is considered a clue of cell
reprogramming [23,24]. However, epigenetic events in various cells
closely provide control of gene expression and genomic regulation
through multiple generations leading to phenotypes' variability.
1.2. Epigenetics in failing heart
Epigenetics are referred to as a modiﬁcation of the non-DNA se-
quences related heritable changes in gene expression of target cells
that is currently recognized as a key to understanding of pathogen-
esis CV diseases [25]. Epigenetic modiﬁcations are based on
different molecular mechanisms, which affect DNA methylation
and deactylation, ATP-dependent chromatin remodeling, histonemodiﬁcations, and microRNA regulation (Fig. 1). All these process-
es coordinate in the modulation of chromatin structure and thereby
might affect the modalities and expression of target genes [26]. It
has been found that the proliferative capability of human cardiac
cells is under tight epigenetic regulation that mediates a dynamic
adaptation of the structure and functionality of wide spectrum of
cells, i.e. cardiomyocytes, ﬁbroblasts, endothelial cells, and progenitor
cells, for environmental challenges and to respond to biochemical
stress. It is suggested that dysregulation in epigenetic signals, messen-
gers and molecular targets is a clue for the pathological remodeling of
the heart and vessels, progenitor cell dysfunction, worsening of the en-
dogenous repair system, and metabolic memory manifestation [27,28].
It is now becoming evident that a cumulative effect of these factorsmay
culminate in HF, cardiac hypertrophy, arrhythmia, dyslipidemia, and
atherosclerosis/atherothrombosis, and associates with increased risk
of CV death [29–34]. Whether interactions between features of tran-
scriptomics, proteomics and metabolomics are speciﬁcally for HFrEF
and HFpEF still remains not clear. Moreover, epigenetics might be a
clue in the mediated transformation of mid-ranged HF deﬁned as HF
with an EF value averaging from 40% to 49% to neither HFrEF nor
HFpEF. The different mechanisms of epigenetic modiﬁcations may
relate to various HF-depended settings, i.e. cardiac hypertrophy,
myocardial infarction, atrial ﬁbrillation, and sudden death, and play a
controversial role (Fig. 2). The epigenetic pattern of distinguished spe-
ciﬁc functional classes of target genes, which regulate the phenotypic
response of a failing heart, is calculated to bemore than 9000 candidate
active enhancers [35]. For example, the histone methyltransferase is
regulated by histone deacetylase inhibition and associated with patho-
logical cardiac hypertrophy and ﬁbrosis, whereas DNA methylation
might directly induce cardiac cavity dilation and reduced pump func-
tion. DNA methylation and histone modiﬁcations interact with several
cell signaling pathways to control target gene expression and might
combinatorially affectenforcing or reversing epigenetic marks in chro-
matin [36]. In this way, none-coding microRNAs that interact with his-
tone modiﬁcation or DNA methylation is able to emerge as the diverse
functions of a failing heart depending on the expression of regulating
target genes acting as fundamental regulators of the transcriptional
reprogramming [37]. However, the innate mechanisms regarding the
causal pathway to HF phenotypes' development are nor fully under-
stood and require more investigations [38].
1.3. DNA methylation
DNAmethylation is themost common epigenetic chromatinmodiﬁ-
cation [39]. Movassagh et al. in 2011 [40] suggested that there are dis-
tinct global patterns of the epigenome leading to the regulation of the
expression of underlying genes. The authors investigated genome-
wide maps of DNA methylation and histone-3 lysine-36 trimethylation
enrichment for cardiomyopathic and normal human hearts. A sufﬁcient
difference in DNA methylation in promoters of up-regulated genes has
been found, but not down-regulated genes in end-stage cardiomyopa-
thy [40]. Furthermore, the process of DNA methylation was under
regulation through several genetic pathways that are modulating by
platelet/endothelial cell adhesion molecule 1, hypoxia-inducible
factor-1 alpha, angiomotin-like 2, and Rho GTPase activating protein
24 [40,41]. The authors suggested that epigenetic modiﬁcations identi-
ﬁed in the failing heart might affect cardiac function directly through
regulation of protein structure synthesis and, indirectly via increased
activity of cardiac ﬁbroblasts due to prolonged hypoxia contributing to
the pro-ﬁbrotic nature of the ischemic milieu.
In contrast, satellite repeat element transcripts, a form of non-coding
RNA that is heavily methylated in post-natal tissue, have putative func-
tions in maintaining genomic stability and chromosomal integrity [42].
Moreover, the hypomethylation of satellite elements exhibited a close
association with signiﬁcant up-regulation of satellite transcripts [43].
Finally, there is evidence that methylation-regulated, alternative
Fig. 1. The principal scheme regarding epigenetic regulations in heart failure development. Abbreviations: α-MHC, the alpha-myosin heavy chain gene, SPR-Ca2+ATPase, sarcoplasmic
reticulum Ca2+ ATPase genes.
33A. Berezin / BBA Clinical 6 (2016) 31–37transcripts might express in a tissue- and cell type-speciﬁc manner and
theymay regulate intragenic promoter activity via enhancing transcrip-
tion elongation efﬁciency [39,43]. Thus, DNAmethylationsmay enhance
transcription of the underlying satellite repeat element transcripts.
Xiao et al. in 2014 [44] reported that increased DNA methylation
might have a causative role in the programming of heart hypertrophy
and reduced global cardiac contractility function. Moreover, impaired
contractility of the left ventricle has been associated with an increase
in the susceptibility to ischemic injury [44]. In contrast, Haas et al. in
2013 [45] did not ﬁnd evidence regarding the participation of DNA
methylation in genes suspected of HF development. However, DNA
methylation has exhibited a causality role in diabetes-induced HFpEF
[46]. Unfortunately, the data regarding the role of DNA methylation in
the development of both phenotypes of HF beyond inhered forms are
very limited, whereas several investigations agree with the hypothesis
that chromatin modiﬁcations act in a combinatorial manner to specify
transcriptional phenotypes in the heart [47]. More investigations areFig. 2. The different mechanisms of epigenetic modiﬁcations involved in the HFrEF and
HFpEF presentation.required to understand the underlying mechanisms linked to DNA
methylation and HF presentation.
1.4. ATP-dependent enzymes in chromatin remodeling
The ATP-dependent chromatin remodeling complexes are not able
to directly modify DNA or histones, whereas they may use the energy
of ATP hydrolysis in processes regarding the destabilization, ejection
or restructuring of nucleosomes, which are a functional unit of
chromatin [48]. Because nucleosomes actively participate in transcrip-
tion, chromosome segregation, DNA replication, and DNA repair, the
chromosomal DNA packaging by nucleosomes is crucial for the regula-
tion of these processes [49]. The dynamic access to DNA packaging is
performed by specialized chromatin remodeling complexes [50].
There are four different families of ATP-dependent chromatin remodel-
ing complexes: switching defective/sucrose non-fermenting complexes
(SWI/SNF), imitation switch complexes, chromodomain–helicase–
DNA-binding complexes, and inositol-requiring eighty complexes [51,
52]. All members of each family exhibit distinct unique domains that
are served to histone–DNA contacts for DNA movement and chromatin
restructuring [53]. The covalently modiﬁed histones are recognized by
these domains of ATP-dependent chromatin remodelers and thereby
regulate an expression of distinct gene programs tailored to speciﬁcity
and biological functions of each family of chromatin remodeling com-
plexes [54].
Recently it has been found that the mitochondrial perturbations
might play a central role in human HF and that epigenetic mechanisms
are crucial for mitochondrial quality control mechanisms [55]. Indeed,
cardiac dysfunction associatedwith volumeoverload correlates tomito-
chondrial damage via increased reactive oxygen species production and
free calciumwithin cardiomyocytes [56]. Evidence for perturbed cardiac
mitochondrial dynamics included decreasedmitochondria size, reduced
numbers ofmitochondria, and an altered expression of genes regulating
fusion and ﬁssion [57]. SWI/SNF that is considered a major regulator of
gene expression might facilitate the shifting and exposure of DNA seg-
mentswithin the promoter and several domains to transcription factors
and other essential cellular proteins [58]. Bultman et al. in 2016 [59] re-
ported the SWI/SNF ATP-dependent chromatin remodeling complexes
in the metabolic homeostasis of the adult cardiac myocytes through
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BRG1 and BRM. Moreover, the authors found that epigenetic mecha-
nisms like SWI/SNF chromatin remodeling have been intimately linked
to cardiac function andmitochondrial quality controlmechanisms. How
several factors including metabolic milieu, aging, and hemodynamic
stress impact on the epigenetic landscape of the myocardium is still
not clear, whereas exploitation of the epigenetic machinery therapeuti-
cally may emerge with clinical relevance [60].
1.5. Histone modiﬁcations
Histonemodiﬁcation represents a dynamic process affecting histone
proteins (H2A, H2B, H3, andH4) that are composed of nucleosomes and
mediated by several enzymes [61]. As a result, distinct histone amino-
terminal modiﬁcations appear to be able to induce synergistic or antag-
onistic interaction afﬁnities for chromatin-associated proteins, which in
turn dictate dynamic transitions between transcriptionally active or
transcriptionally silent chromatin states [62]. By now more than 150
post-translation modiﬁcations of histones have been reported, includ-
ing methylations, acetylations, sumoylation, ubiquitinations, ADP-
ribosylation, proline isomerization, and phosphorylations [63]. The
appearance of conformational changes in chromatin resulting in the
alteration due to histone modiﬁcations regulates gene expression
depending on whether DNA has been became accessible (deﬁned as
euchromatin) or inaccessible (called as heterochromatin) for further
transcription process [64].
Recent studies have shown that histonemodiﬁcation predominantly
methylation closely regulates inﬂammatory and metabolic disorders,
as well as links CV disease and vascular homeostasis [65–67]. There is
evidence that altered redox signaling might mediate trimethylation of
histones H3K4 and H3K9 and thereby links an oxidative stress pathway
with biochemical mechanisms underlying HFrEF development [68].
Probably, aging might affect the development of either HFpEF or
HFrEF through the so-called “epigenetic drift” via marked regulation
of DNA and histone methylation [69]. However, further investigations
are needed to explain in detail the role of histone modiﬁcation in the
impairment of cardiac structure and functionality [70].
1.6. MicroRNA-depending mechanisms
MicroRNAs (miRNAs) are small non-coding RNAs that exert their
function by both transcript degradation and translational inhibition,
resulting in changes in target genes and proteins' expression [71]. It
has been suggested that reactivation of a fetal microRNA program
substantially contributes to alterations of gene expression in the failing
human heart. Indeed, recent studies have shown the increased
expression of miRNA-1, miRNA-21, miRNA-29b, miRNA-129, miRNA-
133, miRNA-208, miRNA-210, miRNA-211, miRNA-212, and miRNA-
423, and miRNA-499 miRNA503 [72–74]. The reduced expression of
miRNA-30, miRNA-182, and miRNA-526 are associated with HF devel-
opment and progression [74]. Therefore, altered microRNA expression
in the human heart was found in ischemic cardiomyopathy, dilated
cardiomyopathy, and aortic stenosis [74–76]. There is evidence that
the disproportion between myocardial expressions of alpha- and beta-
myosin heavy chain (MHC) might be associated with over-expression
of heart-speciﬁc miRNA-208a leading to arrhythmia, ﬁbrosis, and cardi-
ac hypertrophy [77]. Nevertheless, miRNA-208a expression is under
negative control of MED13, a subunit of the mediator complex, which
controls transcription by thyroid hormone and other nuclear hormone
receptors [78]. The down-regulation of miRNA-1 and up-regulation of
miRNA-195 are necessary for cardiac hypertrophy and HFpEF develop-
ment, while the underlying molecular mechanisms of these effects are
still not clear [73,79]. Finally, cardiac hypertrophy may associate with
the activation of Nppa, Nppb, and Acta1 (skeletal α-actin) fetal gene
program [80,81]. It has been deemed that the key components of a car-
diomyocyte hypertrophy mediator might be a miRNA-dependentregulator of calcium signaling pathways [79]. miRNA-24 has exhibited
a regulatory role in failing heart through excitation–contraction
uncoupling of the sarcoplasmic reticulum and T-tubules via the
junctophilin-2 protein [82]. Up-regulated miRNA-24 may suppress
cardiac remodeling associatedwith the accumulation of collagen and ﬁ-
bronectin in a TGF-β-dependent manner [83]. Zhou et al. in 2016 [84]
have found that up-regulated miR-503 in the failing heart might
promote cardiac ﬁbrosis via the miR-503–Apelin-13–TGF-β–CTGF–
collagen production pathway. Other types of miRNAs, i.e. miRNA-21
and miRNA-29 contribute to the development of HF via enhancing
ﬁbrosis by stimulating the extracellular signal-regulated kinase
(ERK)–mitogen-activated protein (MAP) kinase signaling pathway
[85,86]. Moreover, miRNA-29 has been positively associatedwith cardi-
ac hypertrophy and ﬁbrosis [87]. In contrast, over-expressed cardiac-
speciﬁc miRNA-133 may attenuate cardiac ﬁbrosis in an animal model
[88]. miRNA-210 and miRNA-211 are none-cardiac speciﬁc mediators
of mitochondrial function, cell differentiation and growth. Although it
has been found that down-regulation of miRNA-210 has inhibited cell
growth, cell proliferation and induced apoptosis [89], the causal role of
miRNA-210 and miRNA-211 in cardiac remodeling is under investiga-
tion. Hinkel et al. in 2013 [90] have reported that over-expressed
miRNA-92a in the failing heart is a clue of tissue damage and that the in-
hibition of miRNA-92a might protect cardiac myocytes from ischemia/
reperfusion injury.
Theoretically, there is a well-described signature of cardiac-speciﬁc
miRNAs, whichmay be involved in cardiac remodeling formingHF phe-
notypes. Indeed, down-regulatedmiRNA-1, miRNA-29, miRNA-133 and
miRNA-208 in response to cardiac injury or overload correspond to car-
diac hypertrophy, whereas predominantly over-expression of these
miRNAs contributes to cardiacﬁbrosis. An imbalance between regulato-
ry mechanisms affecting expression of miRNA-1, miRNA-29, miRNA-
133 and miRNA-208 might represent speciﬁc HF phenotypes, i.e.
HFrEF or HFpEF [91]. Whether the altered signature of miRNA is consid-
ered a clue for cardiac hypertrophy and dysfunction [81], the low num-
ber of direct clinical evidence regarding speciﬁcally HF phenotypes'
development relating to miRNA signature remains a part of scientiﬁc
discussion [66].
In clinical settings, low circulating levels ofmiRNA-103,miRNA-142-
3p, miRNA-30b, miRNA-342-3p, and miRNA-652-3p and high levels of
miRNA-499 and miRNA-508-5p were found as diagnostic biomarkers
of advanced HF [92–95].Moreover, in advanceHF patients, low circulat-
ing levels of miRNA-423-5p are associated with poor long-term out-
comes [96].
Recently studies have shown thatmiRNAs' deregulation of the endo-
thelial progenitor cells (EPCs) and circulating angiogenic cells involved
in endothelial function modulation might play a key role in HF progres-
sion [93,97,98]. Qiang et al. in 2013 [98] have found that low levels of
miRNA-126 and high levels of miRNA-508a-5p in endothelial progeni-
tor cells were associated with cardiovascular death in ischemia-
induced HF and non-ischemia-induced HF respectively. Furthermore,
decreased miRNA-18a-5p and miRNA-652-3p during a hospitalization
for HF was predictive for 180-day mortality [93]. Whether we can use
the signature of miRNAs measured in EPCs as predictive biomarkers
for HFrEF and HFpEF is not still understood [99].
2. Future direction: epigenetic-based therapies of heart failure?
The impact on molecular targets regulating epigenetic mechanisms
appears to be promised. Several drugsmay inhibit DNAmethyltransfer-
ase directly or by reducing its gene expression, i.e. hydralazine and
procainamide, might have anti-proliferative and anti-inﬂammatory
properties [100]. Therefore, nutrients are currently under investigation
as potent modulators of DNA methyltransferase activity [101]. There
are expectations regarding cardio-protective effects of histone
deacetylase inhibitors, such as valproic acid [100,101]. There is evidence
that histone deacetylase inhibitors may attenuate pathological
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Guvener et al. in 2015 [103] reported that histone deacetylase inhibitor
mocetinostat in HF has exhibited anti-ﬁbrotic effects associated with
the IL-6/STAT3 signalingpathway. Additionally, the regulation of the ex-
pression of microRNA targets is deemed a pharmacological tool for the
prevention of cardiac remodeling and advance of HFpHF and HFrEF
[104–106]. However, no epigenetically active drugs that have actually
entered clinical trials for HFpHF and HFrEF have been approved by the
FDA [107]. Yet, there is uncertainty regarding perspectives of therapeu-
tic strategy based on the inhibition of cardiac hypertrophy in clinical set-
tings [108,109].
In conclusion, the current available data preliminarily clarify that
epigenetic modiﬁcations might be discussed as a clue of forming
phenotypes of HF, whereas there is no strong evidence regarding
epigenetic signatures representing causal pathways leading to speciﬁc
forms of cardiac remodeling associated with HFrEF or HFpEF. Although
epigenetic-based therapies of HF are promised, no large clinical trials
supported the hypothesis regarding the capabilities of DNA methyl-
transferase inhibitors, histone deacetylase inhibitors and miRNAs to
prevent both HF phenotypes from forming. More investigations are re-
quired to discover epigenetic regulation features, because of progress
in this setting which appears to be muchmore promised for translation
to individualized medical care.
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